The vaccine maker's recovery story is looking brighter. Novavax (NVAX 0.81%) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock to a 2,700% gain back in 2020. But when Novavax fell behind on the road to commercialization, the shares declined -- and even the eventual regulatory approval and market entry of that vaccine didn't much help. In recent times, though, Novavax has taken steps t ...